| Trial ID: | L1255 |
| Source ID: | NCT01435174
|
| Associated Drug: |
Ranolazine
|
| Title: |
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01435174/results
|
| Conditions: |
End-stage Renal Disease|Cardiovascular Disease
|
| Interventions: |
DRUG: Ranolazine|PROCEDURE: Pharmacokinetic Blood and Dialysate Sampling|PROCEDURE: QT Interval
|
| Outcome Measures: |
Primary: Pharmacokinetic Parameters of Ranolazine, Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine, At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30, 65 |
|
| Sponsor/Collaborators: |
Sponsor: University of Michigan | Collaborators: Gilead Sciences
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
17
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-10
|
| Completion Date: |
2013-03
|
| Results First Posted: |
2014-06-25
|
| Last Update Posted: |
2017-10-16
|
| Locations: |
University of Michigan Hospital, Ann Arbor, Michigan, 48109, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01435174
|
